Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Decibel Therapeutics, Inc. Announces Extension of Research Term Under Strategic Collaboration with Regeneron to Discover and Develop Gene Therapies for Hearing Loss

11/22/2021 | 07:30am EST

Decibel Therapeutics announced that Regeneron has extended the research term of its collaboration with the Company to discover and develop gene therapies for hearing loss. The research term will be extended to November 15, 2023, and Regeneron will pay Decibel an extension fee of $10 million in Fourth Quarter of 2022. Under the collaboration launched in 2017, Decibel is developing three gene therapy programs targeting congenital, monogenic hearing loss with Regeneron. Decibel plans to initiate in 2022 a Phase 1/2 clinical trial of DB-OTO, the Company?s lead gene therapy product candidate, designed to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. Decibel is also advancing AAV.103 and AAV.104, gene therapy programs targeting other monogenic forms of hearing loss, with Regeneron. AAV.103 aims to restore hearing in individuals with mutations in the GJB2 gene, and AAV.104 aims to restore hearing in individuals with mutations in the STRC gene. Through the collaboration, Regeneron provides Decibel with broad access to its proprietary suite of technologies to support Decibel's goal of discovering new medicines for congenital, monogenic hearing loss. Regeneron also directly participates in and provides financial support for Decibel's research and development efforts under the collaboration through milestone payments and reimbursement intended to fund approximately half of the costs of the collaboration programs. Decibel retains worldwide development and commercialization rights to the product candidates being developed in the collaboration and will pay Regeneron tiered royalties based on net sales.


ę S&P Capital IQ 2021
All news about REGENERON PHARMACEUTICALS
01/25GLOBAL MARKETS LIVE : Credit Suisse, Unilever, Nvidia, Tesla, American Express...
01/25WALL STREET STOCK EXCHANGE : A roller-coaster week as Fed decision looms
01/25MARKETSCREENER’S WORLD PRESS REVIEW : January 25, 2022
01/24REGENERON PHARMACEUTICALS : U.S. Food and Drug Administration Revises Emergency Use Author..
PU
01/24U.S. FDA limits use of Regeneron, Lilly COVID-19 antibody treatments
RE
01/24U.S. FDA to restrict use of Regeneron, Lilly COVID antibody drugs - WaPo
RE
01/24FDA to Restrict Monoclonal Antibodies Manufactured by Eli Lilly, Regeneron Pharmaceutic..
MT
01/24UK to begin testing Merck's COVID pill for hospitalized patients
RE
01/21GSK, Vir ramping up U.S. output of COVID antibody drug
RE
01/21Regeneron - FORTY ACCOMPLISHED YOUNG SCIENTISTS NAMED FINALISTS IN THE 2022 REGENERON S..
AQ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 15 548 M - -
Net income 2021 7 971 M - -
Net cash 2021 4 180 M - -
P/E ratio 2021 8,56x
Yield 2021 -
Capitalization 63 067 M 63 067 M -
EV / Sales 2021 3,79x
EV / Sales 2022 4,18x
Nbr of Employees 9 766
Free-Float 81,7%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 603,19 $
Average target price 697,73 $
Spread / Average Target 15,7%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS-4.49%63 067
GILEAD SCIENCES, INC.-5.19%86 352
VERTEX PHARMACEUTICALS3.42%57 743
WUXI APPTEC CO., LTD.-7.49%50 700
BIONTECH SE-39.30%37 796
BEIGENE, LTD.-13.83%23 988